Inogen, Inc. filed its quarterly report on Form 10-Q with the SEC on November 9, 2026, covering the three and nine months ended September 30, 2026, disclosing a net loss of $16.2 million for the quarter and a $10.6 million impairment charge recorded in the period.

Key Highlights

  • Quarterly net loss: Inogen reported a net loss of $16,155 thousand for the three months ended September 30, 2026, compared to a net loss of $5,294 thousand in the same period of 2025.
  • Impairment charge: A $10,559 thousand impairment charge was recorded in the three months ended September 30, 2026, with no comparable charge in the prior-year quarter.
  • Revenue: Quarterly revenue was $77,193 thousand, down from $79,090 thousand in the three months ended September 30, 2025; nine-month revenue was $233,122 thousand versus $226,732 thousand a year earlier.
  • Goodwill eliminated: Goodwill on the balance sheet fell to $0 as of September 30, 2026, from $10,698 thousand as of December 31, 2025.
  • Share repurchases: During the three months ended September 30, 2026, the company repurchased 641,700 shares of common stock for $3,749 thousand in total.
  • Cash position: Cash and cash equivalents stood at $81,844 thousand as of September 30, 2026, down from $103,729 thousand at December 31, 2025.
  • Shares outstanding: As of October 29, 2026, the registrant had 26,002,082 shares of common stock outstanding.

Inogen's Third Quarter 2026 Financial Results and Impairment Disclosure

According to the filing, Inogen (NASDAQ:INGN) reported total revenue of $77,193 thousand for the three months ended September 30, 2026, a decrease from $79,090 thousand in the comparable prior-year quarter. For the nine months ended September 30, 2026, revenue was $233,122 thousand, up from $226,732 thousand in the nine months ended September 30, 2025. Gross profit for the quarter was $34,008 thousand, compared to $36,165 thousand a year earlier, the company disclosed.

The filing reports that total operating expenses for the three months ended September 30, 2026 were $49,592 thousand, including a $10,559 thousand impairment charge that had no counterpart in the prior-year period. Research and development expenses increased to $5,404 thousand from $4,840 thousand in the prior-year quarter. The loss from continuing operations for the quarter was $14,794 thousand, versus $3,613 thousand in Q3 2025. Loss from discontinued operations, net of tax, was $1,361 thousand for the quarter. Basic and diluted loss per share from continuing operations was $(0.56) for the three months ended September 30, 2026, compared to $(0.13) in the year-ago period.

On the balance sheet, the company disclosed that goodwill stood at $0 as of September 30, 2026, reduced from $10,698 thousand at December 31, 2025, consistent with the impairment charge recorded during the quarter. Total stockholders' equity was $156,989 thousand at September 30, 2026, compared to $192,231 thousand at December 31, 2025. The accumulated deficit widened to $203,913 thousand from $175,584 thousand over the same period. The filing also notes that assets of discontinued operations were $20,574 thousand as of September 30, 2026, down from $32,290 thousand at December 31, 2025, while liabilities of discontinued operations fell to $0 from $4,857 thousand.

What Was Disclosed

Inogen filed its Form 10-Q for the quarter ended September 30, 2026, reporting a net loss of $16,155 thousand, a $10,559 thousand impairment charge, reduced cash, eliminated goodwill, and 641,700 shares repurchased during the quarter.